Radiance Biopharma

Executive Summary

Radiance Biopharma is a private, Boston-based biotechnology company founded in 2019, dedicated to developing next-generation Antibody Drug Conjugates (ADCs) for oncology and other high-unmet-need indications. The company's platform focuses on bispecific Nano ADCs, leveraging a leadership team with deep expertise in oncology drug development. While Radiance is in early stages with no disclosed pipeline or clinical assets, its novel ADC technology aims to improve therapeutic index and overcome resistance mechanisms seen with conventional ADCs. The company is well-positioned in the competitive ADC landscape, which has seen significant recent deal-making and regulatory successes. Key near-term milestones include advancing lead programs toward IND-enabling studies, scaling manufacturing capabilities, and seeking strategic partnerships. Given the promising potential of its platform and experienced team, Radiance represents an early-stage investment opportunity with high upside, albeit with substantial technical and regulatory risk.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead ADC Program60% success
• Q4 2026Presentation of Preclinical Data at Major Conference80% success
• H2 2026Series B Financing or Strategic Partnership70% success